0
0
Verge Genomics Initiates First-In-Human Dosing in Phase 1 Trial of VRG50635, a Novel Therapeutic for Amyotrophic Lateral Sclerosis - Business Wire
10/31/22 at 10:30am
Organization
Business Wire
44 words
0
Comments
Verge Genomics, a clinical-stage, tech-enabled biotechnology company pioneering the use of artificial intelligence (AI) and human data to transform dr
You are the first to view
https://www.businesswire.com/news/home/20221031005225/en/Verge-Genomics-Initiates-First-In-Human-Dosing-in-Phase-1-Trial-of-VRG50635-a-Novel-Therapeutic-for-Amyotrophic-Lateral-Sclerosis
Create an account or login to join the discussion